1. Executive Summary

2. Zika Virus – Introduction, Signs and Symptoms, Transmission, Diagnosis, Treatment & Prevention
2.1 Introduction
2.2 Signs and Symptoms
2.3 Transmission
2.4 Diagnosis
2.5 Treatment
2.6 Prevention

3. Current Situation & Areas with Zika Virus

4. Competitive Landscape of The Zika Virus Vaccines Companies
4.1 Collaborations Deal
4.2 Partnerships & Licensing Agreements Deal

5. Funding in Zika Virus Vaccines Research

6. Zika Virus Vaccines – Clinical Trials Insight by Phase & Trial Status
6.1.1 Zika Vaccines Development: Research Gaps Identified

7. Zika Virus Vaccines – Regulatory Landscape
7.1 Registration Process and Regulations for Vaccines in the US
7.2 Registration Process and Regulations for Vaccines in the EU
7.3 Registration Process and Regulations for Vaccines in Japan

8. Key Companies Analysis
8.1 Sanofi Pasteur
8.1.1 Business Overview
8.1.2 Zika Virus Vaccines - Latest Development and Trends
8.2 ImmunoVaccines Inc.
8.2.1 Business Overview
8.2.2 Zika Virus Vaccines - Latest Development and Trends
8.3 Inovio Pharmaceuticals, Inc.
8.3.1 Business Overview
8.3.2 Inovio Pharmaceuticals, Inc.- Zika Virus Vaccines Analysis
8.3.3 Zika Virus Vaccines - Latest Development and Trends
8.4 Valneva
8.4.1 Business Overview
8.4.2 Zika Virus Vaccines - Latest Development and Trends
8.5 Bharat Biotech International Pvt. Ltd.
8.5.1 Business Overview
8.5.2 Zika Virus Vaccines - Latest Development and Trends
8.6 NewLink Genetics
8.6.1 Business Overview
8.6.2 Zika Virus Vaccines - Latest Development and Trends

Table 3 1: Countries & Territories That Have Reported Mosquito-Borne Zika Virus Transmission
Table 3 2: Countries Reporting Person-To-Person Zika Virus Transmission Since February 2016
Table 3 3: Countries & Territories That Have Reported Guillain-Barre Syndrome (GBS) Potentially Associated with Zika Virus Infection
Table 3 4: Countries & Territories That Have Reported Microcephaly and/or CNS Malformation Cases Potentially Associated with Zika Virus Infection

Table 4 1: Zika Virus Vaccines - Collaborations Deal,2016
Table 4 2: Zika Virus Vaccines - Partnerships Deal,2016
Table 4 3: Zika Virus Vaccines - Licensing Agreements,2016

Table 7 1: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization